title: Predictive value of serum biomarkers in patients after portal vein embolization (PVE): a pilot study.
abstract: OBJECTIVE
  Insufficient growth of the liver or tumor progression is an important issue of portal vein embolization (PVE) in some patients. This study evaluated the predictive value of serum biomarkers for liver hypertrophy and tumor progression after PVE.
  
  
  METHODS
  Serum levels of tumor markers, growth factors and cytokines were determined in 40 patients with malignant liver tumors in the pre- and post-PVE period. The values were compared with contralateral liver hypertrophy and tumor progression.
  
  
  RESULTS
  Liver tissue hypertrophy occurred in 26 (65%), tumor progression in 11 (27.5%) and insufficient liver hypertrophy in 3 (7.5%) of the patients. The significant predictive biomarkers of PVE included serum TPA levels, monototal, IGF-BP3, IGF1, TGF-α, EGF, HGF, VEGF, TNFa and IL-10 before PVE; and TK, TPA, monototal, IGF-BP3, TGFa and IL-8 over the course of 28 days after PVE.
  
  
  CONCLUSIONS
  Certain serum biomarkers have an important predictive value for the result of PVE.
authors.affiliation: Surgical Clinic, Charles University in Pilsen, Czech Republic. treska@fnplzen.cz
authors.forename: Vladislav
authors.initials: V
authors.lastname: Treska
authors.forename: Ondrej
authors.initials: O
authors.lastname: Topolcan
authors.forename: Jindra
authors.initials: J
authors.lastname: Vrzalova
authors.forename: Tomas
authors.initials: T
authors.lastname: Skalicky
authors.forename: Alan
authors.initials: A
authors.lastname: Sutnar
authors.forename: Vaclav
authors.initials: V
authors.lastname: Liska
authors.forename: Jakub
authors.initials: J
authors.lastname: Fichtl
authors.forename: Andrea
authors.initials: A
authors.lastname: Narsanska
authors.forename: Jiri
authors.initials: J
authors.lastname: Ferda
authors.forename: Inka
authors.initials: I
authors.lastname: Treskova
authors.forename: Hyne
authors.initials: H
authors.lastname: Mirka
authors.forename: Boris
authors.initials: B
authors.lastname: Kreuzberg
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000473:pathology / Q000628:therapy; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000556:secondary / Q000628:therapy; D015179:Colorectal Neoplasms / Q000097:blood* / Q000473:pathology / Q000628:therapy; D004621:Embolization, Therapeutic; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008113:Liver Neoplasms / Q000097:blood* / Q000556:secondary / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011169:Portal Vein / Q000378:metabolism; D011379:Prognosis; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor